MedTrace Logo

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

NCT01327521 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-06-11

No results posted yet for this study

Summary

Primary Objective:

To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE.

Secondary Objectives:

1. To determine the progression-free survival of TACE vs. CyberKnife SBRT
2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC
3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DEVICE

CyberKnife

Standard of Care

PROCEDURE

TACE

Standard of Care

DRUG

CT Contrast

Standard of Care

DRUG

doxorubicin

Standard of Care

DRUG

Epirubicin

Standard of Care

DRUG

5-fluorouracil

Standard of Care

DRUG

Mitomycin C

Standard of Care

DRUG

Gemcitabine

Standard of Care

DRUG

Cisplatin

Standard of Care

DEVICE

SMANCS

Standard of Care

Sponsors & Collaborators

  • Accuray Incorporated

    collaborator INDUSTRY

  • Albert Koong

    lead OTHER

Principal Investigators

  • Albert Koong · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327521 on ClinicalTrials.gov